Description: Mesoblast is developing a series of high margin, off-the-shelf adult stem cell products that are obtained from a single donor, commercially expanded and frozen, and subsequently used in potentially thousands of unrelated, or allogeneic, recipients at the time and place of need.
Home Page: www.mesoblast.com
55 Collins Street
Melbourne,
VIC
3000
Australia
Phone:
61 3 9639 6036
Officers
| Name | Title |
|---|---|
| Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director |
| Dr. Eric A. Rose M.D. | Chief Medical Officer & Exec. Director |
| Mr. Andrew Chaponnel B.Com. | Interim Chief Fin. Officer |
| Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S. | Chief Operating Officer |
| Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons) | Gen. Counsel & Corp. Exec. |
| Mr. Roger D. Brown BA | Head of Spinal Orthopedic Disorders |
| Mr. Michael Schuster M.B.A., MS, BSc, MBA | Head of Pharma Partnering |
| Ms. Geraldine Storton B.Sc., M.B.A., Bsc, MMS, MBA | Head of Regulatory Affairs & Quality Management |
| Mr. Justin Horst B.S. | Head of Manufacturing |
| Ms. Niva Sivakumar B.Com., L.L.B. | Joint Company Sec. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 769.2308 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9158 |
| Price-to-Sales TTM: | 68.0958 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 77 |